ACADIA Pharmaceuticals Inc.
ACAD
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.8B
$28.02
▲ +0.57%
P/E
12.57
Mkt Cap
$4.8B
52-Wk Range
$19.69–$30.96
52-Week Range
$19.69 - $30.96
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 10.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized neurological disorder focus
- Advanced drug development pipeline
- FDA-approved flagship product NUPLAZID
- Targeted therapeutic approach
Bear Case
2 risks
- Average volatility.
- High premium - requires strong execution
Growth
Moderate growth ahead
Expanding neurological treatment market
Value
High premium - requires strong execution
Momentum
Hot
+29.1% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying ACAD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 4, 2026
Reported EPS of $0.18 vs $0.07 consensus (+164.1% surprise). Revenue of $308.0M vs $296.6M expected (+3.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+164.1%
Revenue trend · last 8Q
—
+12%
+19%
+9%
+11%
+9%
+10%
+16%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$250.4M
$259.6M
$244.3M
$264.6M
$278.6M
$284.0M
$268.1M
$308.0M
Margins · last 8Q
Gross
-79.0%
Operating
12.3%
Profit
10.2%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$36.50
▲ +30.3% vs $28.02
Latest: Deutsche Bank · Aug 25, 2026
2 analysts covering
vs Industry
How ACAD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related